Which UK patent covers Rybrevant (amivantamab)?
Rybrevant (amivantamab) is protected in the UK through a mix of patent filings and UK “lifecycle” protections such as supplementary protection certificates (SPCs) and related patent rights tied to the underlying molecule and approved use. The exact number(s) depend on what you mean by “covers” (for example, the original invention patent versus later patents for formulation, dosing, combination regimens, or specific indications).
To identify the specific UK patent(s) you need, the key input is which product/term you’re looking for:
- the earliest EP/WO family that led to UK rights for the drug substance,
- an SPC in the UK (if any) linked to the first marketing authorization date, or
- patents that specifically claim a method of treatment (including combinations).
If you tell me the UK meaning you want (drug substance, a specific indication, or the combo regimen), I can narrow down what to search.
How do you find the Rybrevant patent in the UK (practical search steps)?
In the UK, the most reliable way to pinpoint the active rights is to search across:
- UK Intellectual Property Office (UKIPO) patent register for “amivantamab” and the applicant/assignee name(s).
- UK “registers” and status pages that show whether there is an SPC tied to a marketing authorization for Rybrevant.
- Patent family mapping from the earliest filing (often via EP/WO numbers) to see which members entered the UK.
Search terms that usually work: “amivantamab”, “Rybrevant”, “Janssen” (and related corporate names), and the key early WO/EP family identifier once known.
When does the UK exclusivity/patent protection for Rybrevant expire?
UK “exclusivity” can refer to more than one thing:
- the expiry of the underlying patent term,
- potential extension via SPCs,
- and sometimes data/exclusivity protection that is not the same as patent expiry.
Because the protection end-date depends on the particular UK patent/SPC and the relevant marketing authorization dates, you need the specific UK patent or SPC number to compute the correct timeline.
Can biosimilars enter the UK before Rybrevant’s UK patents expire?
Usually no for the targeted claims, because biosimilar entry is constrained by whatever patents (and SPCs) are still in force in the UK for the claimed product and/or use. Even if regulatory approval processes exist, commercial launch is typically blocked by patent coverage until those rights expire or are cleared via licensing or court outcomes.
What happens if there’s an SPC for amivantamab in the UK?
If an SPC exists, it extends the time protection for the active ingredient beyond the base patent term, but only within the limits of:
- the specific claims covered by that SPC,
- and the permitted duration rules tied to regulatory authorization.
This is why two different UK patents in the same family can have different effective “end dates” for market exclusion.
If you want, I can identify the exact UK patent/SPC numbers—what details should you share?
Reply with one of these and I’ll help you map it to the likely UK protection:
1) the UK indication you care about (e.g., NSCLC with EGFR exon 20 insertion, or a combination regimen), or
2) whether you mean “drug substance patent” vs “SPC”, or
3) the earliest filing/patent family number you’ve seen (WO/EP/US number), or
4) the UK link you’re using (UKIPO/SPC search result, or a patent number you already suspect).
Sources
No sources were provided in your message, and I don’t have enough specific information (patent/SPC number, application owner, or indication) to cite the correct UK patent records for Rybrevant.